Clinical trials of anticoagulant for percutaneous coronary intervention in patients undergoing primary PCI

TrialResults-center www.trialresultscenter.org

1 Low Molecular Weight Heparin

Trial	Treatments	Patients	Trials design and methods
enoxaparin vs UFH			
ATOLL , 2010 n=450/460 follow-up: 30 days	IV enoxaparin versus UFH	patients undergoing PCI for acute STEMI	Parallel groups open Austria, France, Germany, and US
Brieger n=346/234 follow-up:	enoxaparin versus unfractionated heparin	patients undergoing percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI)	

References

ATOLL, 2010:

Brieger, :

Brieger D, Collet JP, Silvain J, Landivier A, Barthlmy O, Beygui F, Bellemain-Appaix A, Mercadier A, Choussat R, Vignolles N, Costagliola D, Montalescot G Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention. Catheter Cardiovasc Interv 2011;77:182-90 [20578166] 10.1002/ccd.22674

Entry terms: Lovenox, Clexane

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.